Abstract: A general methodology for the synthesis of substituted quinolin-4-amines developed by us previously has been simplified. The synthesized compounds, depending on substituents, show activities in the range from 35 nM to 550 nM as antagonists of immunostimulatory oligodeoxynucleotides containing a CpG motif. A SAR analysis is presented.

CpG motifs in DNA of vertebrates contain mostly 5-methylcytosine. By contrast, the CpG motifs with unmethylated cytosine are common in bacterial DNA, and stimulate immune responses in vertebrates. Single-stranded synthetic CpG-containing oligodeoxynucleotides and phosphorothioate oligodeoxynucleotides (CpG-ODN) are also immunostimulatory. This finding has led to the development of a simple assay in vitro for the search of compounds that inhibit the immunostimulatory effect. Several agents that are active in this in vitro assay induce remissions of rheumatoid arthritis and systemic lupus erythematosus, suggesting the involvement of CpG-DNA in these autoimmune diseases. In our previous work we synthesized and assayed many classes of compounds and showed that several substituted 2-arylquinolin-4-amines are the most potent antagonists of the immunostimulatory CpG-ODN found to date. The assayed quinolines contained diverse 2-aryl and 4-amino groups but had no substituents at other positions of the quinolines system. This report pertains to the synthesis and biological evaluation of a series of new 2-aryl-4-{[2-(dimethylamino)ethyl]amino}quinolines that contain an additional substituent at the 6 or 7 position (Scheme 1). The 2-(dimethylamino)ethylamino function was chosen for all quinolines because such derivatives, in general, show high activity. Pairs of quinolines without and with the 6- or 7-substituent were synthesized and assayed for a direct analysis of the effect of the substituent.

The desired compounds 13 – 27 (Scheme 1) were synthesized by condensation of 2-(trifluoromethyl)anilines 1-5 with aryl methyl ketones 6-11 followed by cyclization of the resultant ketimines 12 by treatment with a lithium derivative of 2-(dimethylamino)ethylamine. Previously, this general methodology called for the use of analytically pure intermediate ketimines 12. As part of this work it was found that prepurification by a simple bulb-to-bulb distillation, giving 12 of about 90% purity, was adequate. In addition, tetrahydrofuran was substituted for ether as solvent in the subsequent cyclization reactions of 12, which resulted in slightly increased yields of the quinoline products. Compounds 13 – 27 were obtained by using this modified methodology.

The effective concentrations (EC₅₀) for 50% inhibition of the CpG-ODN mediated effect vary from 35 nM for 14 to 550 nM for 24 and 25 (Scheme 1). Comparison of the EC₅₀ values for pairs of compounds composed of an identical 2-arylquinoline system, e.g. 14/18 and 15/20, reveals that the presence of a fluorine atom at the position 6 of the quinolines decreases the activity. A similar effect is observed for 6-chloro substitution (compare 13/22 and 16/23). However, the largest decrease in activity is seen for the 7-trifluoromethyl substituted quinolines (e.g. 14/24 and 15/26). Interestingly, the 4-(trifluoromethyl)phenyl substituted quinolines 17 and 21 also exhibit relatively low activities. The highest EC₅₀ values were obtained for compounds 14 – 16 that are devoid of a trifluoromethyl group. These results have important ramifications for the design of new antagonists.
Improved synthesis of substituted 2-aryl-N-[2-dimethylamino)ethyl] Quinolin-4-amines and their activity

Scheme-1: Synthesis of quinolines 13 – 27 and their activities as Antagonists of Immunostimulatory CpG-Oligodeoxynucleotides

*EC_{50} is an effective concentration for 50% inhibition by quinoline antagonists of the immunostimulatory effect of CpG-ODN. The ability of test compounds to reverse the action of CpG-ODN on WEHI 231 murine lymphoma B-cells was assessed in vitro as described previously.

**Experimental**

**General.** Tetrahydrofuran was distilled from sodium benzophenone ketyl immediately before use. 2-(Dimethylamino)ethylamine was dried over solid KOH. Unless stated otherwise, ^1^H NMR spectra (400 MHz) were obtained in DMSO-\textsubscript{d}_6 solutions. Electron-impact mass spectra were obtained at 70 eV.

**Quinolines 13 – 27.** A solution of a 2-(trifluoromethyl)aniline 1 – 5 (0.03 mmol), a ketone 6 – 11 (0.02 mmol), and a catalytic amount of p-toluenesulfonic acid in xylenes was heated under reflux for several hours until no ketone was detected by TLC analysis (silica gel, hexanes/ether, 9:1). After cooling, xylenes and the excess aniline were removed on a rotary evaporator, and the oily residue was distilled from the same flask by using bulb-to-bulb distillation (150 – 230 °C/0.5 mmHg) to give 12 of about 90% purity (GC analysis).
A solution of 2-(dimethylamino)ethylamine (0.66 mL, 6 mmol) in tetrahydrofuran (15 mL) was treated a solution of n-butyllithium in cyclohexane (2 M, 3 mL, 6 mmol) at -10 °C, and the resultant mixture was stirred at -10 °C for 20 min before treatment with a solution of ketimine 12 (1.5 mmol). The mixture was stirred at -10 °C for an additional 1 h and then quenched with water (0.5 mL). The organic layer was concentrated on a rotary evaporator, and the residue was purified by silica gel chromatography (hexanes/Et2O/1,2:1). A simple removal of a colored polymeric material on a short silica gel column was sufficient for a crystalline product which was further purified by crystallization from hexanes or hexanes/AcOEt. The purification of an oily quinoline required the use of a conventional chromatographic procedure. The noncrystalline product was additionally purified by crystallization of its hydrobromide salt. Thus a solution of a quinoline in EtOH was treated with a solution of hydrobromic acid (3 molar equiv) in EtOH/H2O (9:1), and the resultant mixture was concentrated to precipitate the hydrobromide salt. The salt was crystallized twice from EtOH or EtOH/hexanes. The composition was determined by elemental analysis.

2-(Chlorophenyl)-N-[2-(dimethylamino)ethyl]quinolin-4-amine (13). This compound has been characterized previously.

N-[2-(Dimethylamino)ethyl]-2-(2-fluoro-4-methoxyphenyl)quinolin-4-amine dihydrobromide (17·2HBr·1.5H2O). Yield 88%; mp 198-200 °C; 1H NMR (CDCl3) δ 2.37 (s, 6H), 2.79 (t, J = 6 Hz, 2H), 3.44 (m, 2H), 6.13 (br s, exchangeable with D2O), 6.82 (s, 1H), 7.47 (t, J = 8 Hz, 1H), 7.68 (t, J = 8 Hz, 1H), 7.74 (d, J = 8 Hz, 2H), 8.09 (d, J = 8 Hz, 1H), 8.20 (d, J = 8 Hz, 2H). Anal. calcd for C20H20F2N3·2HBr·1.5H2O: C, 59.33; H, 4.64; N, 13.36. Found: C, 58.90; H, 4.58; N, 13.48.

N-[2-(Dimethylamino)ethyl]-6-fluoro-2-(2-fluoro-4-methoxyphenyl)quinolin-4-amine dihydrobromide (18·2HBr). Yield 76%; mp 268-270 °C; 1H NMR (free base in CDCl3) δ 2.33 (s, 6H), 2.71 (t, J = 6 Hz, 2H), 3.34 (t, J = 6 Hz, 1H), 7.12 (m, 1H), 7.43 (m, 3H), 7.82 (m, 2H), 8.05 (m, 1H); EI-MS m/z 58 (100), 357 (M+). Anal. calcd for C16H15F2N·2HBr: C, 46.26; H, 4.46; N, 8.09. Found: C, 46.00; H, 4.50; N, 8.15.

This compound has been characterized previously.

N-[2-(Dimethylamino)ethyl]-6-fluoro-2-(4-fluorophenyl)quinolin-4-amine dihydrobromide (21). Yield 65%; mp 179-180 °C; 1H NMR (CDCl3) δ 7.13 (s, 1H), 7.41 (m, 1H), 7.85 (m, 2H), 8.18 (d, J = 8 Hz, 1H); EI-MS m/z 58 (100), 377 (M+). Anal. calcd for C16H15FN·2HBr: C, 63.65; H, 5.07; N, 11.13. Found: C, 63.64; H, 5.03; N, 11.17.

N-[2-(Dimethylamino)ethyl]-6-fluoro-2-(4-fluorophenyl)quinolin-4-amine dihydrobromide (22·2HBr·H2O). Yield 40%; mp 213-215 °C; 1H NMR (CDCl3) δ 2.24 (s, 6H), 2.69 (t, J = 6 Hz, 2H), 3.20 (t, J = 6 Hz, 2H), 5.83 (br s, exchangeable with D2O), 6.07 (s, 1H), 7.36 (m, 2H), 7.48 (m, 1H), 4.60 (m, 2H), 7.79 (m, 1H), 7.98 (d, J = 9 Hz, 1H); EI-MS (free base) m/z 58 (100), 360 (M+). Anal. calcd for C16H15FN·2HBr·H2O: C, 42.24; H, 4.29; N, 7.77. Found: C, 41.98; H, 4.32; N, 7.71.

N-[2-(Dimethylamino)ethyl]-6-fluoro-2-(4-fluorophenyl)quinolin-4-amine dihydrobromide (23). Yield 69%; mp 197-198 °C; 1H NMR (CDCl3) δ 7.13 (s, 1H), 7.41 (m, 1H), 7.85 (m, 2H), 8.26 (d, J = 8 Hz, 1H), 8.38 (s, 1H). Anal. calcd for C16H15FN·2HBr·H2O: C, 42.24; H, 4.29; N, 7.77. Found: C, 41.98; H, 4.32; N, 7.71.
Improved synthesis of substituted 2-aryl-N-[2-dimethylamino)ethyl]quinolin-4-amines and their activity

Vol. 13, No. 1, 2007

Vol. 13, No. 1, 2007 Improved synthesis of substituted 2-aryl-N-[2-dimethylamino)ethyl]quinolin-4-amines and their activity

(N-[2-(Dimethylamino)ethyl]-7-trifluoromethyl-2-[(3-fluoro)phenyl]quinolin-4-amine (25). Yield 66%; mp 117-119 °C; \( ^1H \) NMR (CDCl\(_3\)) \( \delta 2.37 \) (s, 6 H), 2.78 (t, \( J = 6 \) Hz, 2 H), 3.42 (t, \( J = 6 \) Hz, 2 H), 6.15 (s, 1 H), 6.87 (s, 1 H), 7.14 (m, 1 H), 7.47 (m, 1 H), 7.60 (m, 1 H), 7.89 (m, 3 H), 8.35 (s, 1 H); EI-MS m/z 58 (100), 377 (M\(^+\)). Anal. calcd for C\(_{21}\)H\(_{21}\)F\(_4\)N\(_3\): C, 61.90; H, 5.19; N, 10.31. Found: C, 61.83; H, 5.20; N, 10.31.

\( N\)-[2-(Dimethylamino)ethyl]-7-trifluoromethyl-2-[(3-fluoro-4-methoxy)phenyl]quinolin-4-amine (26·2HBr·H\(_2\)O). Yield 40%; mp 245-247 °C; \( ^1H \) NMR (free base in CDCl\(_3\)) \( \delta 2.37 \) (s, 6 H), 2.79 (t, \( J = 6 \) Hz, 2 H), 3.96 (s, 3 H), 6.25 (br s, exchangeable with D\(_2\)O), 6.83 (s, 1 H), 7.07 (t, \( J = 8 \) Hz, 1 H), 7.57 (m, 1 H), 7.89 (m, 3 H), 8.13 (s, 1 H); EI-MS (free base) m/z 58 (100), 277 (35), 349 (45), 407 (M\(^+\)). Anal. calcd for C\(_{21}\)H\(_{19}\)F\(_4\)N\(_3\)·2HBr·H\(_2\)O: C, 42.94; H, 4.29. Found: C, 43.01; H, 4.35.

Biological Evaluation

The ability of test compounds to reverse the action of CpG-ODN on WEHI 231 murine lymphoma B-cells was assessed as described previously.\(^6\,10\)

References

Received on July 10, 2006.